潤啤(00291.HK)去年賺45.87億人民幣不及盈喜預測上限 午後股價跌幅擴至近6%
藍籌華潤啤酒(00291.HK)去年純利45.87億人民幣(早前發盈喜時預測純利介乎44億至47億元人民幣)。該股午後跌幅擴大兼失守10天線(49港元),最低見47.8港元,現報48.5港元,回吐5.8%,成交達1,130萬股,已接近昨天全日成交量。
潤啤中午公佈,去年純利按年升近1.2倍至45.87億元人民幣(下同),每股盈利1.41元,末期股息按年增1.3倍至0.302元。期內,總營收按年升6.2%至333.87億元。整體毛利率按年升0.8個百分點至39.2%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.